Figure 6C illustrated that those individuals with low PD-1 expression levels and low SRGS scores had a longer OS than those with low PD-1 expression levels and high SRGS scores. In individuals with strong PD-1 expression levels, a lower risk score indicated a survival rate that was significantly improved. In the TCGA-AML cohort, similar survival trends were identified across the four AML patient groups stratified by the SRGS scores and CTLA4 (Figure 6F) or LAG3 (Figure 6I) expression. This evidence concerns the gene CTLA4 and acute myeloid leukemia.